Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP

Current human papillomavirus (HPV) vaccines provide substantial protection against the most common HPV types responsible for oral and anogenital cancers, but many circulating cancer-causing types remain for which vaccine coverage is lacking. In addition, all current HPV vaccines rely on aluminum sal...

Full description

Bibliographic Details
Main Authors: Sarah M. Valencia, Athina Zacharia, Alexander Marin, Rebecca L. Matthews, Chia-Kuei Wu, Breana Myers, Chelsea Sanders, Simone Difilippantonio, Reinhard Kirnbauer, Richard B. Roden, Ligia A. Pinto, Robert H. Shoemaker, Alexander K. Andrianov, Jason D. Marshall
Format: Article
Language:English
Published: Taylor & Francis Group 2021-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
human papillomavirus
hpv
prophylactic vaccine
pcep
polyphosphazenes
adjuvants
hpv-l2
neutralizing antibody
Online Access:http://dx.doi.org/10.1080/21645515.2021.1875763

Similar Items

Similar Items